Gilead Sciences Inc (GILD)

65.55
0.00(0.00%)
  • Volume:
    15
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    57.39 - 57.39
Trading near 52-week High

Gilead Sciences Inc has hit the highest price it has traded for over the last year (52 week period). This is a technical indicator that can be used to analyze the stock's current value and predict future price movement.

1 / 3

GILD Overview

Prev. Close
65.55
Day's Range
57.39-57.39
Revenue
27.04B
Open
57.39
52 wk Range
57.39-57.39
EPS
4.45
Volume
15
Market Cap
102.6B
Dividend (Yield)
3.00
(4.58%)
Average Vol. (3m)
15
P/E Ratio
17.83
Beta
0.399
1-Year Change
0%
Shares Outstanding
1,248,816,053
Next Earnings Date
-
What is your sentiment on Gilead Sciences Inc?
or
Market is currently closed. Voting is open during market hours.

Gilead Sciences Inc Company Profile

Gilead Sciences Inc Company Profile

Employees
14400
  • Type:Equity
  • Market:Chile
  • ISIN:US3755581036

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, and Stribild. The Company’s COVID-19 product is Veklury. The Company’s also provides Epclusa, Harvoni, Vemlidy, and Viread products for liver diseases. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The Company’s other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.

Read More

Analyst Price Target

Average92.08 (+18.22% Upside)
High115.00
Low77.00
Price77.89
No. of Analysts29
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts Consensus

Technical Summary

Type
Daily
Weekly
Monthly
Moving Averages
Technical Indicators
Summary
  • Who cares about dividends when this stock shows weakness year after year, is not a good deal to get 5% per year if you are constantly worried about this stock sinks under 2013 lows
    0
    • Are you a coinbase client? 😉
      0
  • it sucks...
    1
    • invest stock gild.us at basel markets to take home divedends
      0
      • Projected earnings beat but I'd bet it doesn't move the needle -
        0
        • Another 15 or so shares into this.
          1
          • I've held this since 2014 or so. COULD have picked NVDA for approx 15 - 20 😒Did I pick the winner eh?
            2
            • Amazing how GILD managed to disappoint on EVERY earnings report.
              4
              • Yes, even a beat is disapointing -
                0
            • What's happening?!
              1
              • Everyone in market is here to make money. Gilead saved my wife's life. I will donate all my money for this one organization who is working to safe our life ...
                1
                • I a, donating money for good cause, buying Gilead
                  0